Research finds RAGE removal significantly reduces breast cancer spread in older mice — Evidence Review
Published in Communications Biology, by researchers from Georgetown Lombardi Comprehensive Cancer Center
Researched by
— the AI search engine for science
Table of Contents
Scientists at the Georgetown Lombardi Comprehensive Cancer Center have identified a cellular receptor, RAGE, that helps explain why breast cancer is more likely to metastasize as we age. Related research broadly supports the idea that aging alters the body’s environment in ways that can promote cancer progression and worsen outcomes.
- The new study’s finding that RAGE drives age-related breast cancer metastasis in mice aligns with previous research showing that the aging microenvironment—including increased inflammation—fosters tumor progression and impacts therapy response 1 7.
- Related studies demonstrate that both very young and older breast cancer patients have poorer prognoses, but the mechanisms differ; in the elderly, systemic changes such as chronic inflammation and altered immune responses play key roles, supporting the clinical relevance of RAGE as a therapeutic target 2 5 7.
- Existing literature also identifies other age-related systemic factors, such as methylmalonic acid accumulation and immune system aging, that promote tumor aggressiveness, reinforcing the importance of understanding and targeting age-associated biological changes in cancer management 8 11.
Study Overview and Key Findings
Breast cancer risk and mortality increase with age, but the biological reasons for this trend have remained unclear. Most laboratory research on breast cancer has traditionally used young animal models, overlooking the influence of age-related changes in the body. This new study leverages an unexpected opportunity created by the COVID-19 pandemic, which allowed researchers to study cancer progression in older mice, shedding light on how systemic aging-related factors can facilitate tumor spread.
The research highlights the role of the receptor for advanced glycation end-products (RAGE) in mediating age-associated breast cancer metastasis. By demonstrating that removal or inhibition of RAGE nearly eliminates the increased metastatic risk in older mice, the study provides a mechanistic link between aging and cancer spread, and suggests new avenues for therapeutic intervention.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Georgetown Lombardi Comprehensive Cancer Center |
| Journal Name | Communications Biology |
| Authors | Philip Miller, Sunita Chopra, Melinda Magna, Jiaxiang Tao, Carlos Benitez, Thomas Heist, Nanette H. Bishopric, Jeanne S. Mandelblatt, Julia Panov, Joyce M. Slingerland, Barry I. Hudson |
| Population | Older mice, breast cancer patients |
| Sample Size | n=1000 patients |
| Methods | Animal Study |
| Outcome | Breast cancer metastasis, inflammatory gene expression |
| Results | RAGE removal nearly eliminated cancer spread in older mice. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus database (over 200 million papers) for relevant research. The following search queries were used:
- RAGE cancer spread older mice
- breast cancer age-related mortality
- mechanisms of cancer progression aging
Related Study Themes and Findings
| Topic | Key Findings |
|---|---|
| How does aging influence breast cancer progression and metastasis? | - Aging increases breast cancer metastasis in animal models, largely driven by systemic factors such as RAGE and inflammatory ligands 1 7. - Age-related metabolic and immune changes, like increased methylmalonic acid and altered myelopoiesis, can promote tumor aggressiveness and metastatic potential 8 11. |
| What is the relationship between patient age and breast cancer outcomes? | - Both younger (<40) and older (>75/80) breast cancer patients have poorer survival, but likely due to different mechanisms 2 3 5 6. - Disease-specific mortality rises with age in hormone receptor-positive breast cancer, independent of stage at diagnosis 2 5. |
| What are the mechanisms by which the aging microenvironment promotes cancer? | - The aged microenvironment, including increased chronic inflammation, changes in secreted factors, and altered immune responses, fosters tumor progression and therapy resistance 1 7 9 10. - Specific molecules such as S100 proteins, HMGB1, methylmalonic acid, and IL-1α are implicated in creating a metastasis-promoting environment 1 8 11. |
| Are there therapeutic targets or interventions for age-related cancer progression? | - Inhibition of RAGE or its ligands can suppress metastasis in aged animal models, suggesting potential clinical applications 1. - Other age-associated systemic factors (e.g., MMA, IL-1α) may also serve as therapeutic targets, but translation to human cancer therapy requires further study 8 11. |
How does aging influence breast cancer progression and metastasis?
Multiple studies confirm that aging increases the risk of breast cancer metastasis, not only through prolonged exposure to carcinogenic factors but also via systemic biological changes. The new study’s identification of RAGE as a key mediator aligns with previous research showing that the aging microenvironment—including increased inflammation and metabolic alterations—creates conditions that promote tumor aggressiveness and spread.
- Aging in mice increases metastatic potential, particularly via inflammatory signaling and RAGE activation 1 7.
- Metabolic byproducts like methylmalonic acid and shifts in immune cell composition further contribute to tumor progression with age 8 11.
- These findings support the idea that targeting age-associated pathways could mitigate metastatic risk in older patients 1 8.
- The use of older animal models, as in the new study, provides more clinically relevant insights compared to traditional studies using only young animals 7.
What is the relationship between patient age and breast cancer outcomes?
Epidemiological studies consistently demonstrate that both very young and older women with breast cancer have worse outcomes, though the underlying causes differ. In older patients, higher disease-specific mortality is often attributed to systemic changes such as immune dysfunction, chronic inflammation, and altered tumor-host interactions.
- Older age (>75/80 years) is associated with worse survival, independent of stage at diagnosis 2 5.
- Young age (<40 years) also predicts poorer prognosis, particularly in certain subtypes like hormone receptor-positive or luminal breast cancers 3 5 6.
- The current study’s focus on the aged host environment complements existing findings by offering new mechanistic insights into why older patients are at greater risk 1 2.
- Clinical data linking high RAGE gene expression with poor outcomes in breast cancer patients suggests translational relevance 1.
What are the mechanisms by which the aging microenvironment promotes cancer?
The aging body undergoes changes that collectively foster a tumor-permissive environment. These include increased chronic inflammation, shifts in secreted factors, immune system aging, and accumulation of pro-tumorigenic molecules. The new study’s identification of RAGE as a central player in these processes is supported by literature that highlights similar pathways.
- Cellular senescence, altered extracellular matrix, and chronic inflammation are hallmarks of the aging microenvironment that promote cancer progression and metastasis 7 9 10.
- RAGE, S100 proteins, HMGB1, methylmalonic acid, and IL-1α are among the molecules implicated in driving tumor-promoting changes with age 1 8 11.
- Some mechanisms of aging (e.g., genomic instability, inflammation) overlap with cancer hallmarks, while others may have antagonistic effects 9 10.
- Understanding these pathways is important for developing age-specific cancer therapies 1 7.
Are there therapeutic targets or interventions for age-related cancer progression?
Targeting pathways that mediate the interplay between aging and cancer progression is an emerging area of interest. The new study demonstrates that inhibiting RAGE or its ligands can significantly reduce metastasis in aged animal models, supporting the exploration of such interventions in clinical settings.
- Pharmacological inhibition of RAGE with agents like TTP488 has shown efficacy in reducing metastasis in preclinical breast cancer models 1.
- Other molecules implicated in age-related tumor progression, such as MMA and IL-1α, are also being investigated as potential therapeutic targets 8 11.
- The translation of these findings from animal models to human patients is ongoing and requires careful assessment of safety and efficacy 1 8.
- Age-specific interventions may help tailor cancer treatment to improve outcomes in older adults 1 7.
Future Research Questions
Despite advances in understanding how aging promotes breast cancer progression, several important questions remain. Further research is needed to clarify the mechanisms involved, evaluate therapeutic interventions in human populations, and determine how best to personalize cancer care for older adults.
| Research Question | Relevance |
|---|---|
| Does RAGE inhibition reduce breast cancer metastasis in older human patients? | The current evidence for RAGE’s role is based on animal models; clinical trials are needed to determine whether RAGE inhibitors can safely and effectively reduce metastasis in older breast cancer patients 1. |
| What other systemic age-related factors promote cancer progression? | Studies have identified molecules like methylmalonic acid and IL-1α as pro-tumorigenic in aged individuals, suggesting additional targets for intervention beyond RAGE 8 11. |
| How does the aging immune system influence breast cancer outcomes? | Immune system aging alters tumor surveillance and response, potentially impacting both cancer progression and treatment efficacy in older patients 7 8. |
| Are there biomarkers that predict metastatic risk in older breast cancer patients? | Identifying reliable biomarkers (e.g., RAGE, S100 proteins, inflammatory gene signatures) could allow clinicians to assess risk and personalize therapy for older adults 1 7 11. |
| How do age-related changes in the tumor microenvironment affect response to cancer therapies? | The aged microenvironment can influence both metastasis and treatment response, potentially explaining why older patients may respond differently to therapy; further research may guide the development of age-adapted treatment strategies 7 10. |